BIOCOM Supports The Citizens Initiative To Build Multi-Use Sports Complex And Convention Facility In San Diego

SAN DIEGO, Aug 29, 2016 /PRNewswire/ -- Biocom, the association representing the California life science industry, today announced that its board has voted to endorse Proposition C, the Chargers' Citizens Initiative, in San Diego, with certain conditions to be addressed by the Chargers, as endorsed by the San Diego Chamber of Commerce.

"Attracting and retaining employees in San Diego is essential to continuing to build a thriving life sciences community," said Joe Panetta, president and CEO of Biocom. "The region boasts a high quality of life that is very attractive, and an integral part of that is active sports franchises like the Chargers. For this reason, Biocom is endorsing the Chargers' Citizens Initiative.

"In addition," continued Panetta. "Prop C expands our convention center, which will ensure that San Diego will continue to attract the caliber of scientific and medical meetings that attract life scientists here."

About Biocom
Biocom is the largest, most experienced leader and advocate for California's life science sector. We work on behalf of more than 750 members to drive public policy, build an enviable network of industry leaders, create access to capital, introduce cutting-edge STEM education programs, and create robust value-driven purchasing programs.

Founded in 1995 in San Diego, Biocom provides the strongest public voice to research institutions and companies that fuel the local and state-wide economy.  Our goal is simple: to help our members produce novel solutions that improve the human condition. In addition to its San Diego headquarters, Biocom operates a core office serving the Los Angeles market, satellite offices in Washington, D.C. and Tokyo, and has a continuous staff presence in Sacramento. Our broad membership benefits apply to biotechnology, pharmaceutical, medical device, genomics and diagnostics companies of all sizes, as well as to research universities and institutes, clinical research organizations, investors and service providers. Connect with us on LinkedIn, Facebook, and Twitter (@BIOCOMCA).


To view the original version on PR Newswire, visit:


Back to news